相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.
Matthew H. G. Katz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis
Tobias Forster et al.
ONCOLOGY (2020)
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis
Kelvin K. W. Chan et al.
CANCER MEDICINE (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Michelle Chan-Seng-Yue et al.
NATURE GENETICS (2020)
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
Afsaneh Barzi et al.
PANCREAS (2020)
Liposomal Irinotecan+5-FU/LV in Metastatic Pancreatic Cancer Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
Teresa Macarulla Mercade et al.
PANCREAS (2020)
The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies
Pedro Luiz Serrano Uson Junior et al.
PLOS ONE (2020)
ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
Paula Ghaneh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
Valeria Merz et al.
CANCERS (2020)
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Valeria Merz et al.
CLINICAL CANCER RESEARCH (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
D. J. Renouf et al.
ANNALS OF ONCOLOGY (2020)
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
M.L. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
Dilara Akhoundova Sanoyan et al.
CASE REPORTS IN ONCOLOGY (2020)
First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study
Julien Taieb et al.
ESMO OPEN (2020)
Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
Victor H. F. de Jesus et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
Susanna Hegewisch-Becker et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Molecular subtypes of pancreatic cancer
Eric A. Collisson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
Teresa Macarulla et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites
Melanie S. Patzak et al.
EBIOMEDICINE (2019)
Drug resistance in pancreatic cancer: New player caught in act
Gabriele Capurso et al.
EBIOMEDICINE (2019)
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu et al.
ACTA PHARMACEUTICA SINICA B (2019)
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
Martin R. Jones et al.
CLINICAL CANCER RESEARCH (2019)
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
Li-Tzong Chen et al.
CANCERS (2019)
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
Maximilian Brunner et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
N. Stjepanovic et al.
ANNALS OF ONCOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
Richard A. Hubner et al.
EUROPEAN JOURNAL OF CANCER (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
An update on treatment options for pancreatic adenocarcinoma
Aurelien Lambert et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
Markus Kieler et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Marc Hilmi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
Anjali V. Sheahan et al.
Oncotarget (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
664PPhase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)
M Alsina et al.
ANNALS OF ONCOLOGY (2018)
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
Andrew McGuigan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX
Victor Hugo Fonseca de Jesus et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACACT trial
Josep Tabernero et al.
ONCOTARGETS AND THERAPY (2017)
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC).
Maria Alsina et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
More deaths from pancreatic cancer than breast cancer in the EU by 2017
J. Ferlay et al.
ACTA ONCOLOGICA (2016)
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
Sharlene Gill et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Daniel Zeitouni et al.
CANCERS (2016)
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Werner Scheithauer et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Alix Portal et al.
BRITISH JOURNAL OF CANCER (2015)
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
David Fogelman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Helmut Oettle et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
Hiroshi Haeno et al.
CELL (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
分享论文
